Efflux Pump Overexpression Profiling in Acinetobacter baumannii and Study of New 1-(1-Naphthylmethyl)-Piperazine Analogs as Potential Efflux Inhibitors.

Antimicrobial Agents and Chemotherapy
Morgane ChoquetCatherine Mullié

Abstract

Overexpression of efflux pumps extruding antibiotics currently used for the treatment of Acinetobacter baumannii infections has been described as an important mechanism causing antibiotic resistance. The first aim of this work was to phenotypically evaluate the overexpression of efflux pumps on a collection of 124 ciprofloxacin-resistant A. baumannii strains. An overexpression of genes encoding one or more efflux pumps was obtained for 19 out of the 34 strains with a positive phenotypic efflux (56%). The most frequent genes overexpressed were those belonging to the RND family, with adeJ being the most prevalent (50%). Interestingly, efflux pump genes coding for MATE and MFS families were also overexpressed quite frequently: abeM (32%) and abaQ (26%). The second aim was to synthesize 1-(1-naphthylmethyl)-piperazine analogs as potential new efflux pump inhibitors and biologically evaluate them against strains with a positive phenotypic efflux. Quinoline and pyridine analogs were found to be more effective than their parent compound, 1-(1-naphthyl methyl)-piperazine. Stereochemistry also played an important part in the inhibitory activity, as quinoline derivative (R)-3a was identified as being the most effective and less cytotoxic...Continue Reading

References

Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Jacqueline ChevalierJean-Marie Pagès
Mar 23, 2005·BMC Bioinformatics·Alexey LarionovWilliam Miller
Apr 15, 2006·Clinical Microbiology Reviews·Laura J V Piddock
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Lilian PumbweHannah M Wexler
Dec 13, 2006·Nature Reviews. Drug Discovery·Olga LomovskayaWilliam J Watkins
Feb 10, 2007·The Journal of Antimicrobial Chemotherapy·Narcisa MesarosFrançoise Van Bambeke
Apr 19, 2008·The Journal of Infectious Diseases·Louis B Rice
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Jun 17, 2009·Journal of Medical Microbiology·Yagang ChenLanjuan Li
Oct 6, 2009·Journal of Microbiological Methods·Faustino Vidal-ArocaJürg Dreier
Dec 10, 2009·The Journal of Antimicrobial Chemotherapy·Paul G HigginsHarald Seifert
Jun 18, 2010·The Journal of Antimicrobial Chemotherapy·Michael HornseyNeil Woodford
Aug 11, 2010·Antimicrobial Agents and Chemotherapy·Sébastien CoyneBruno Périchon
Dec 22, 2010·Antimicrobial Agents and Chemotherapy·Sébastien CoyneBruno Périchon
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Aug 14, 2013·Antimicrobial Agents and Chemotherapy·C RumboUNKNOWN Spanish Network for Research in Infectious Diseases(REIPI)
Jan 6, 2015·The Journal of Microbiology·Young Kyoung Park, Kwan Soo Ko
Jun 10, 2015·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Ming-Feng LinChung-Yu Lan
Jun 9, 2016·BioMed Research International·Sirijan Santajit, Nitaya Indrawattana
Mar 5, 2017·Essays in Biochemistry·Mohsen Chitsaz, Melissa H Brown
Mar 16, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Gabriella SpenglerLeonard Amaral
Feb 6, 2018·American Journal of Infection Control·Katja WielandRalf-Peter Vonberg
Jun 27, 2018·Antimicrobial Agents and Chemotherapy·María Pérez-VarelaJordi Barbé
Jun 14, 2019·New Microbes and New Infections·C XuW Xu
Jun 21, 2019·Pharmaceuticals·Pierre LaumailléPascal Sonnet

❮ Previous
Next ❯

Methods Mentioned

BETA
NMR
column chromatography
PCR

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.